Dr. Lal PathLabs Limited announced key decisions following its Board of Directors meeting on July 24, 2026. The board approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, declared an interim dividend of INR 5 per equity share, and greenlit strategic acquisitions in Ghana and India. The company also approved the grant of stock options under its Employee Restricted Stock Unit Plan.
Financial Results and Dividend Approved
The Board of Directors of Dr. Lal PathLabs Limited, in their meeting held on July 24, 2026, took several significant decisions. Primary among these was the approval of the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. Accompanying these results is a Limited Review Report from the Statutory Auditors.
Further enhancing shareholder value, the Board approved the declaration of an interim dividend of INR 5 per equity share (at 50% on a face value of INR 10 each) for the Financial Year 2026-27. The record date for this dividend payment has been set as July 30, 2026, with the dividend to be paid within 30 days of declaration.
Strategic Acquisitions and Stock Options
In line with its growth strategy, the company’s Board also approved the acquisition of a stake in Sunshine Healthcare Limited (“SHL”) in Ghana by its wholly owned subsidiary, Dr Lal PathLabs FZCO, Dubai. Additionally, Dr. Lal Ventures Private Limited, another wholly owned subsidiary, received approval for the acquisition of a stake in Neuome Technologies Private Limited.
The Board also approved the granting of 119,300 stock options under the Dr. Lal PathLabs Employee Restricted Stock Unit Plan 2025 to eligible employees. These options are exercisable at the face value of the share as on the grant date and will vest between one and four years from the grant date.
Acquisition Details
The acquisition of Sunshine Healthcare Limited in Ghana involves acquiring an 80% stake in the first tranche, with further tranches planned. SHL’s turnover for FY 2026 is projected at INR 244 million. The acquisition aims to strengthen the company’s presence in Ghana’s healthcare diagnostics sector.
The investment in Neuome Technologies Private Limited entails subscribing to a 30% stake for up to INR 35 million. Neuome is involved in developing innovative solutions for sample preservation, pre-analytical technologies, and bio-banking. The acquisition is expected to be completed by August 31, 2026.
Meeting Details
The Board Meeting commenced at 10:45 A.M. (IST) and concluded at 01:30 P.M. (IST) on July 24, 2026.
Source: BSE
